Literature DB >> 26449381

Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute.

Sham Mailankody1, Vinayak Prasad2.   

Abstract

Mesh：

Year:  2015        PMID： 26449381      PMCID： PMC4718435          DOI： 10.1634/theoncologist.2015-0323

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  10 in total

1.  Novel_target.com.

Authors:  T Fojo
Journal:  Oncologist       Date:  2001

Review 2.  Multidrug resistance in cancer: role of ATP-dependent transporters.

Authors:  Michael M Gottesman; Tito Fojo; Susan E Bates
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

3.  How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Authors:  Tito Fojo; Christine Grady
Journal:  J Natl Cancer Inst       Date:  2009-06-29       Impact factor: 13.506

4.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Authors:  Tito Fojo; Sham Mailankody; Andrew Lo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

5.  Washington report: a conversation with Vincent T. DeVita, Jr., M.D.. Interview by Daniel S. Greenberg.

Authors:  V T DeVita
Journal:  N Engl J Med       Date:  1980-10-23       Impact factor: 91.245

6.  Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Authors:  Wilfred D Stein; James L Gulley; Jeff Schlom; Ravi A Madan; William Dahut; William D Figg; Yang-Min Ning; Phil M Arlen; Doug Price; Susan E Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-11-24       Impact factor: 12.531

7.  Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

Authors:  Jame Abraham; Manish Agrawal; Susan Bakke; Ann Rutt; Maureen Edgerly; Frank M Balis; Brigitte Widemann; Louis Davis; Bharat Damle; Daryl Sonnichsen; David Lebwohl; Susan Bates; Herb Kotz; Tito Fojo
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

8.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

Review 9.  CNS metastasis: an old problem in a new guise.

Authors:  Jeanny B Aragon-Ching; Jo Anne Zujewski
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

10.  P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.

Authors:  V Sandor; A Senderowicz; S Mertins; D Sackett; E Sausville; M V Blagosklonny; S E Bates
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.